1. Pink Sheet
  2. >>Product Reviews

Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments

 
• By Michael Cipriano

State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.

Trump_Donald_160716_1200x675

President Trump offered a more glowing assessment of the FDA in his first official State of the Union address, but also touched on two areas that could make industry feel uneasy: drug pricing and "right-to-try" legislation.

After previously slamming FDA as having burdensome regulations at a joint session of Congress last year, Trump praised the agency for its record numbers of medical product approvals

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 
• By Eliza Slawther

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 
• By Neena Brizmohun

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 
• By Anju Ghangurde

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.